Tags

Type your tag names separated by a space and hit enter

Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis.
Am J Trop Med Hyg. 2004 Nov; 71(5):577-81.AJ

Abstract

The cost of generic pentavalent antimony (generic stibogluconate) is approximately one-sixth that of branded pentavalent antimony (stibogluconate in the form of Pentostam or meglumine antimoniate in the form of Glucantime. We compared generic stibogluconate to Pentostam and Glucantime for the treatment of cutaneous leishmaniasis patients in Bolivia and Colombia. For all 114 patients, the per-protocol cure rates were 83-91% and the intent-to-treat cure rates were 75-83%. The highest values were in the generic stibogluconate group. The incidence of pancreatic enzyme abnormalities was 48-88% and the incidence of liver enzyme abnormalities was 48-87%. The lowest incidences were in the generic stibogluconate group. The efficacy and tolerance of inexpensive generic stibogluconate appears comparable to branded formulations for the treatment of cutaneous leishmaniasis in these endemic regions.

Authors+Show Affiliations

Consorcio de Investigaciones Bioclínicas, Calle 60 A 5-54, Suite 201, Bogota, Colombia. jaime.soto@cable.net.coNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15569787

Citation

Soto, J, et al. "Comparison of Generic to Branded Pentavalent Antimony for Treatment of New World Cutaneous Leishmaniasis." The American Journal of Tropical Medicine and Hygiene, vol. 71, no. 5, 2004, pp. 577-81.
Soto J, Valda-Rodriquez L, Toledo J, et al. Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis. Am J Trop Med Hyg. 2004;71(5):577-81.
Soto, J., Valda-Rodriquez, L., Toledo, J., Vera-Navarro, L., Luz, M., Monasterios-Torrico, H., Vega, J., & Berman, J. (2004). Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis. The American Journal of Tropical Medicine and Hygiene, 71(5), 577-81.
Soto J, et al. Comparison of Generic to Branded Pentavalent Antimony for Treatment of New World Cutaneous Leishmaniasis. Am J Trop Med Hyg. 2004;71(5):577-81. PubMed PMID: 15569787.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis. AU - Soto,J, AU - Valda-Rodriquez,L, AU - Toledo,J, AU - Vera-Navarro,L, AU - Luz,M, AU - Monasterios-Torrico,H, AU - Vega,J, AU - Berman,J, PY - 2004/12/1/pubmed PY - 2005/1/19/medline PY - 2004/12/1/entrez SP - 577 EP - 81 JF - The American journal of tropical medicine and hygiene JO - Am J Trop Med Hyg VL - 71 IS - 5 N2 - The cost of generic pentavalent antimony (generic stibogluconate) is approximately one-sixth that of branded pentavalent antimony (stibogluconate in the form of Pentostam or meglumine antimoniate in the form of Glucantime. We compared generic stibogluconate to Pentostam and Glucantime for the treatment of cutaneous leishmaniasis patients in Bolivia and Colombia. For all 114 patients, the per-protocol cure rates were 83-91% and the intent-to-treat cure rates were 75-83%. The highest values were in the generic stibogluconate group. The incidence of pancreatic enzyme abnormalities was 48-88% and the incidence of liver enzyme abnormalities was 48-87%. The lowest incidences were in the generic stibogluconate group. The efficacy and tolerance of inexpensive generic stibogluconate appears comparable to branded formulations for the treatment of cutaneous leishmaniasis in these endemic regions. SN - 0002-9637 UR - https://www.unboundmedicine.com/medline/citation/15569787/Comparison_of_generic_to_branded_pentavalent_antimony_for_treatment_of_new_world_cutaneous_leishmaniasis_ L2 - https://www.diseaseinfosearch.org/result/4166 DB - PRIME DP - Unbound Medicine ER -